Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma
Language English Country England, Great Britain Media print-electronic
Document type Letter, Observational Study
PubMed
38847436
DOI
10.1111/ijd.17285
Knihovny.cz E-resources
- Keywords
- anti‐CTLA‐4, anti‐PD‐1, lenvatinib, metastatic melanoma, pembrolizumab, pretreated patients,
- MeSH
- Quinolines * therapeutic use administration & dosage adverse effects MeSH
- Adult MeSH
- Phenylurea Compounds * administration & dosage MeSH
- Antibodies, Monoclonal, Humanized * adverse effects therapeutic use administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Melanoma * drug therapy secondary pathology MeSH
- Skin Neoplasms * drug therapy pathology MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Letter MeSH
- Observational Study MeSH
- Names of Substances
- Quinolines * MeSH
- Phenylurea Compounds * MeSH
- Antibodies, Monoclonal, Humanized * MeSH
- lenvatinib MeSH Browser
- pembrolizumab MeSH Browser
See more in PubMed
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Five‐year analysis of adjuvant pembrolizumab or placebo in Stage III melanoma. NEJM Evid. 2022;1:1–12.
Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five‐year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–1546.
Arance A, de la Cruz‐Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP‐004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein‐1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41:75–85.
Stoff R, Asher N, Laks S, Steinberg Y, Schachter J, Shapira‐Frommer R, et al. Real world evidence of Lenvatinib + anti PD‐1 as an advanced line for metastatic melanoma. Front Oncol. 2023;13:1–7.
